Skip to content
DataLookout
Menu

T-STEMNCT07825857

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Oct 23, 2026
    • Site details revised at 4 of 4 sites
  2. Minor Study sites: 3 to 4
  3. Minor Study description expanded, about 9 words
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment response
Timeframe: 26 weeks

Secondary (6)

Tolerability - stopping of treatment
Current craving for methamphetamine
Early remission
Safety - occurrence of serious adverse event
Reduction in self-reported use of methamphetamine
Show 1 moreShow less
Worst past-week craving for methamphetamine

Arms and interventions

TirzepatideExperimental

Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 26-week period.

Placebo (Saline)Placebo comparator

Eligible participants who are enrolled will receive once-weekly subcutaneous injections of saline for a 26-week period.

Drugs: Tirzepatide, Placebo (saline)

Sites

4 sites in 1 country